An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Apitolisib (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Genentech
- 10 Jun 2017 Biomarkers information updated
- 19 Jan 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 07 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.